Palvella Advances FDA Filing as Drug Spending Lifts Loss
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) began its rolling U.S. application for QTORIN rapamycin during the second quarter as higher clinical, manufacturing and regulatory spending more than doubled …
Palvella Advances FDA Filing as Drug Spending Lifts Loss Read More